Temporal Concept – Page 21

GE HealthCare and UCSF Launch ‘Care Innovation Hub’ to Revolutionize Medical Imaging for Cancer and Neurodegenerative Diseases

8 months ago talkbio0Tagged Automated (qualifier value), brain health, ELAVL2 gene, GE HealthCare, innovation, Magnetic Resonance Imaging, Medical Imaging, Neoplasms, Neurodegenerative Disorders, Precision - temporal, radiopharmaceutical therapies, UCSF

GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.

BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025

8 months ago talkbio0Tagged 2025, Attruby, BridgeBio Pharma, Clinical Trials, commercial, FORTIFY, Hereditary Diseases, milestones, Phase 3, Propel, status - In progress

BridgeBio Pharma, Attruby, commercial progress, pipeline updates, 2025 milestones, rare genetic diseases, Phase 3 clinical trials, FORTIFY, CALIBRATE, PROPEL 3.

FDA Sets Efficacy Threshold for Obesity Therapies Amid Market Expansion

8 months ago talkbio0Tagged Effectiveness, Market, Obesity, standards characteristics, trends qualifier, United States Food and Drug Administration, Weight-Loss

FDA, obesity therapies, weight-loss treatments, efficacy standards, obesity market trends

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

8 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies

8 months ago talkbio0Tagged Cancer Therapeutic Procedure, Funding, genetic editing, Light Horse, Novartis, Precision - temporal, Series, small molecule therapeutics

Light Horse Therapeutics, Novartis, Series A funding, cancer therapies, small molecule therapeutics, precision genetic editing platform

Light Horse Therapeutics Secures $1 Billion+ Novartis Collaboration on Launch Day

8 months ago talkbio0Tagged Drug Discovery, Genome Editing, Light Horse, Novartis, Precision - temporal, small molecule therapeutics, strategic collaboration

Light Horse Therapeutics, Novartis, biotech, strategic collaboration, small molecule therapeutics, precision genome editing, drug discovery

Breakthrough in Graft-Versus-Host Disease Treatment: MaaT013 Microbiome Therapy Shows Unprecedented Efficacy

8 months ago talkbio0Tagged acute, Fecal Microbiota Transplantation, Graft-Versus-Host Disease, GvHD, MaaT013, Microbiome Therapy, Precision - temporal, Science of nutrition, Steroid-Resistant

Graft-Versus-Host Disease (GvHD), Microbiome Therapy, MaaT013, Acute GvHD, Steroid-Resistant GvHD, Faecal Microbiota Transplantation, Precision Nutrition

Fierce Health Payer Summit 2025: Shaping the Future of Healthcare Payers

8 months ago talkbio0Tagged Behavior, Fierce, Health, Health Payer Summit, Healthcare Industry, Healthcare Payers, payer-provider alignment, trends qualifier, Value-Based Care

Fierce Health Payer Summit, healthcare payers, value-based care, behavioral health, payer-provider alignment, healthcare industry trends.

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

9 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement

Biotech Industry’s Turbulent Year: Fierce Biotech’s Top 10 Most-Read Stories of 2024

9 months ago talkbio0Tagged Biopharma, biotech industry, J.P. Morgan Healthcare, M&A, rejections, shutdowns, trends qualifier, United States Food and Drug Administration

Biotech industry, layoffs, site shutdowns, FDA rejections, M&A deals, J.P. Morgan Healthcare Conference, biopharma trends